Home › Urothelial (Transitional Cell) Carcinoma › Minnesota › Minneapolis
Urothelial (Transitional Cell) Carcinoma clinical trials in Minneapolis, MN
3 studies for Urothelial (Transitional Cell) Carcinoma are looking for participants at sites in and around Minneapolis (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
RecruitingPhase 3
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi away
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RecruitingPhase 2
- Hennepin County Medical Center, Minneapolis
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
RecruitingPhase 1/2
- M Health Fairview University of Minnesota Medical Center, Minneapolis
Urothelial (Transitional Cell) Carcinoma trials in other cities
- Nashville, TN23 studies
- New York City, NY22 studies
- Houston, TX19 studies
- Dallas, TX18 studies
- Edison, NJ18 studies
- Los Angeles, CA17 studies
- Queens, NY15 studies
- Chicago, IL14 studies
- Arlington, VA12 studies
- Boston, MA11 studies
- San Antonio, TX11 studies
- Austin, TX10 studies
Other studies in Minneapolis
- Non-Small Cell Lung Cancer27 studies
- Breast Cancer27 studies
- Ovarian Cancer24 studies
- Prostate Cancer23 studies
- Cancer (all types)22 studies
- Heart Failure21 studies
- Acute Myeloid Leukemia20 studies
- Lung Cancer20 studies
- Colorectal Cancer19 studies
- Endometrial Cancer18 studies
- Parkinson's Disease17 studies
- Cardiovascular Disease15 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.